ADMA Biologics (ADMA) Misses Q3 EPS by 9c

ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of ($0.48), $0.09 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.85 million versus the consensus estimate of $1.5 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Ocean Power Technologies revises fiscal 2026 results after audit
• TJX stock drops as profit outlook falls short of analyst estimates